Brief: LIDDS: Liproca Depot Open Label Extension Study Indicates PSA Reduction For Up To One Year
23/10/2019 07:38
Oct 23 (Reuters) - Lidds AB LIDDS.ST :
* REG-LIDDS: LIPROCA® DEPOT OPEN LABEL EXTENSION STUDY
INDICATES
PSA REDUCTION FOR UP TO ONE YEAR
* STUDY INDICATES LONGER PSA EFFECT WITH LIPROCA® DEPOT IN
PROSTATE CANCER PATIENTS THAN ANTICIPATED
Source text for Eikon: ID:nGNE9yWgms
Further company coverage: LIDDS.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Lidds AB
See all newsBrief: Liquidator To Apply For Lidds To Be Declared Bankrupt
Brief: Lidds To Delist Shares From Nasdaq First North
Brief: Lidds Proposes Voluntary Liquidation And Delisting
Brief: Lidds Decides To Terminate Process Regarding Reverse Acquisition Of Proport Invest
Brief: Lidds Signs Agreement For Reverse Takeover Of Proport Invest